Hubbry Logo
Air trappingAir trappingMain
Open search
Air trapping
Community hub
Air trapping
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Air trapping
Air trapping
Air trapping
View on Wikipedia
from Wikipedia
A CT image showing bonchiolitis obliterans with ground glass pattern, air trapping and bronchial thickening.

Air trapping, also called gas trapping, is an abnormal retention of air in the lungs where it is difficult to exhale completely.[1] It is observed in obstructive lung diseases such as asthma, bronchiolitis obliterans syndrome and chronic obstructive pulmonary diseases such as emphysema and chronic bronchitis.

Air trapping is not a diagnosis but is a presentation of an illness, and can be a guide to the appropriate differential diagnosis.

Imaging

[edit]

Computed tomography (CT) is the most sensitive imaging modality for detecting air trapping. On inspiratory CT scans, air trapping may appear as areas of decreased attenuation (darker areas), often described as mosaic attenuation. The diagnostic hallmark is persistence of these low-attenuation areas on expiratory CT, during which normal lung parenchyma increases in attenuation (or becomes whiter) while trapped air remains lucent.[2] Expiratory imaging is therefore essential for confirming air trapping and distinguishing it from vascular causes of mosaic attenuation.[3]

Measurement and function

[edit]

Exhaled volumes are measured by a pulmonary function test or simple spirometry, leading to an elevated residual volume and a measurement of forced expiratory volume. Air trapping is often incidentally diagnosed on computed tomography (CT) scanning. On expiratory films, retained hyperlucent gas will be visualised in cases of air trapping.[4]

Air trapping represents poorly aerated lung, but on its own is clinically benign. It is a common problem for smokers who dive. On diving the lung volume collapses and pushes air into the poorly aerated regions. On arising from a deep depth, these air-trapped areas of lung expand. This places great pressure on the lung tissue which can rupture.[5]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Air trapping

View on Grokipedia
from Grokipedia
Air trapping, also known as gas trapping, is a pathophysiological phenomenon in pulmonary medicine characterized by the abnormal retention of air in the distal to partial or complete obstruction of the small airways during expiration, resulting in incomplete emptying and lung hyperinflation. This condition manifests as parenchymal areas with less than normal increase in and lack of volume reduction on end-expiratory computed (CT) scans, as defined by the Fleischner Society. It is a key feature of obstructive lung diseases such as (COPD), , , , and , where trapped air reduces the space available for fresh , exacerbating breathing difficulties.

Definition and Physiology

Definition

Air trapping is defined as the abnormal retention of excess air in the lungs during expiration, resulting from partial or complete obstruction of the airways, which leads to of the affected lung regions. This phenomenon occurs distal to the site of obstruction, primarily involving the alveoli and small airways, where exhaled air fails to escape fully due to narrowed or collapsed passages. The concept of air trapping was first described in the context of obstructive lung diseases in the early , with observations of slowed expiration in using early spirometric recordings and radiographic assessments of lung volumes during breathing cycles. These initial insights highlighted the retention of air as a key feature distinguishing obstructive pathologies from normal respiratory mechanics. Importantly, air trapping represents the dynamic physiological process of incomplete exhalation that precipitates , whereas refers to the resultant static increase in lung volume beyond normal limits. In conditions such as (COPD), air trapping exacerbates airflow limitation and contributes to disease progression.

Normal Lung Physiology

In normal lung physiology, tidal breathing involves a coordinated cycle of inspiration and expiration that maintains without residual air retention. During inspiration, the diaphragm contracts and descends, increasing the vertical dimension of the , while the elevate the to expand the anteroposterior and transverse dimensions, creating negative that draws air into the s. Expiration, in contrast, occurs passively during quiet breathing as the inspiratory muscles relax, allowing the of lung tissue and chest wall to decrease thoracic volume and expel air. The airways play a critical role in ensuring efficient during expiration, particularly the small airways with internal diameters less than 2 mm, which lack significant cartilaginous support and rely on surrounding alveolar attachments and to remain patent. , produced by type II alveolar cells, reduces at the air-liquid interface, preventing collapse of these peripheral airways as lung volume decreases. At the alveolar level, healthy lungs exhibit uniform dynamics characterized by even distribution of ventilation and , enabling optimal through a ventilation-perfusion (V/Q) ratio close to 1 across most lung units. This matching is facilitated by complete emptying of alveoli during each expiratory cycle, where and minimal allow full evacuation of inspired air beyond when required. A key physiological parameter in this process is the residual volume (RV), which represents the air remaining in the lungs after maximal expiration and is typically 1.2-1.5 L in healthy adults, serving as the baseline volume that prevents complete alveolar without trapping.

Pathophysiology and Causes

Mechanisms of Air Trapping

Air trapping occurs primarily through the narrowing or of small airways during expiration, resulting from the loss of radial traction provided by surrounding alveolar walls that normally tether and support airway patency. This structural disruption allows intraluminal pressure to drop below the surrounding pleural pressure, promoting premature airway closure and retention of air in distal lung units. A key biomechanical process underlying this phenomenon is dynamic airway compression, where the positive pleural pressure generated during forced expiration exceeds the intraluminal pressure in small airways, leading to their collapse before full exhalation. This is explained by the equal pressure point theory, in which an intraluminal point of equilibrium shifts upstream during expiration; beyond this point, the accelerating airflow causes a pressure decrease according to , reducing airway wall pressure and facilitating compression. Inflammation and mucus hypersecretion further exacerbate air trapping by inducing and increasing , which prolongs the expiratory . The (τ), defined as the product of (R) and (C), quantifies this delay in regional lung emptying: τ=R×C\tau = R \times C Regions with elevated R due to or mucus plugging exhibit longer τ values, resulting in incomplete exhalation and heterogeneous air retention across the . This uneven emptying contributes to ventilation-perfusion (V/Q) mismatch, creating areas of low V/Q ratios where perfusion continues despite reduced ventilation, impairing gas exchange and promoting hypoxemia. Such disparities arise as trapped air limits alveolar expansion in affected regions, diverting ventilation to better-perfused areas while underperfused zones remain hypoventilated. This mechanism is particularly evident in conditions like emphysema, where parenchymal destruction amplifies these effects.

Associated Conditions

Air trapping commonly occurs as a secondary feature in various obstructive lung diseases, where it arises from airway obstruction and loss of . In (COPD), particularly the emphysema subtype, alveolar wall destruction leads to decreased lung elasticity and premature airway collapse during expiration, resulting in hyperinflation and gas retention. , another key obstructive condition, features reversible and that can cause dynamic air trapping, especially during acute exacerbations, though it is often less persistent than in COPD. Other respiratory conditions also contribute to air trapping through distinct mechanisms of obstruction. involves fibrotic narrowing of small airways, leading to mosaic attenuation and air trapping visible on expiratory computed , often as a of or . In , viscous mucus plugging obstructs bronchioles, promoting air trapping and contributing to progressive lung hyperinflation. Swyer-James syndrome, a rare post-infectious disorder, manifests as unilateral hyperlucent lung with reduced vascularity and air trapping due to bronchiolar obliteration and alveolar . Non-disease factors can induce focal or diffuse air trapping. , particularly in children, causes localized obstruction and ball-valve effects that trap air distal to the blockage, leading to on the affected side. Iatrogenic air trapping may result from with excessive (PEEP), which promotes intrinsic PEEP and gas retention in patients with underlying . Epidemiologically, air trapping is most prevalent in smokers with COPD, where it affects a of cases due to tobacco-induced airway ; for instance, residual volume/total capacity ratios exceeding 40%—indicative of —are observed in over 50% of heavy smokers with early signs. In , viral , often caused by , frequently involves air trapping, contributing to . A notable genetic is , which accelerates development and air trapping in smokers by impairing protease inhibition, leading to unchecked alveolar destruction even at lower smoking exposures.

Clinical Manifestations

Symptoms

The primary symptom of air trapping is dyspnea, characterized by that initially occurs during physical exertion due to the increased from lung hyperinflation. As the condition progresses, dyspnea may worsen to occur at rest, reflecting the persistent retention of air in the alveoli and reduced expiratory flow rates. This sensation often feels like air hunger or unsatisfying breaths, stemming from the mechanical disadvantage imposed by overinflated lungs. Other common manifestations include wheezing, resulting from turbulent through narrowed or obstructed airways, and a that typically produces minimal in cases dominated by air trapping, such as in . In pure air trapping scenarios without significant overlap, the is often dry and non-productive, contrasting with more mucus-laden coughs in other obstructive diseases. The presentation of symptoms can vary between acute and chronic forms; in acute exacerbations, such as during attacks, air trapping leads to sudden worsening of dyspnea and wheezing due to rapid airway closure and dynamic hyperinflation. Conversely, in chronic conditions like COPD, symptoms develop insidiously over years, with gradual intensification of breathlessness linked to progressive air retention. Air trapping significantly impacts daily life, causing reduced exercise tolerance as even mild activities provoke severe breathlessness, and , where lying flat exacerbates dyspnea due to further diaphragmatic flattening from . Patients often report limitations in routine tasks, such as walking short distances or completing sentences without pausing to breathe. Severity of dyspnea in air trapping-related obstruction is commonly graded using the modified Medical Research Council (mMRC) dyspnea scale, a validated tool that assesses breathlessness impact on activities from grade 0 (no limitation) to grade 4 (too breathless to leave the house). This scale helps quantify symptom burden in associated obstructive diseases like COPD and .

Physical Examination Findings

During physical examination, patients with air trapping often exhibit signs of pulmonary hyperinflation, characterized by an increased anteroposterior diameter of the chest, resulting in a barrel-shaped appearance where the thoracic ratio exceeds 0.9. This hyperinflation may also manifest as widened intercostal spaces, elevated clavicles, and a shortened neck, reflecting chronic lung overexpansion. Use of accessory respiratory muscles, such as the sternocleidomastoid and scalene muscles, is commonly observed, particularly in severe cases with significant airflow obstruction. Auscultation reveals prolonged expiratory phase, often exceeding 6 seconds during forced expiration, indicating obstructive . Breath sounds are typically diminished or reduced in intensity over affected areas due to air trapping and reduced . Percussion yields a hyperresonant note, extending below the fifth in the midclavicular line, which is a strong predictor of underlying obstruction. may demonstrate reduced tactile , attributable to the buffering effect of trapped air in the s. Associated findings include , a compensatory mechanism that prolongs expiration and maintains to alleviate dyspnea. In severe cases, central may appear due to from impaired . Clinical assessment of can involve qualitative grading based on chest excursion and , though quantitative scales inspired by radiographic features are sometimes adapted for bedside evaluation.

Diagnosis

Imaging Modalities

Chest X-ray is often the initial imaging modality for evaluating air trapping, revealing signs of such as flattened diaphragmatic contours and an increased retrosternal measuring greater than 2.5 cm on the lateral view. These findings indicate overall overexpansion due to trapped air but are limited in assessing dynamic changes during respiration, as the technique provides only static images without expiratory phases. High-resolution computed tomography (HRCT) serves as a more sensitive tool for detecting air trapping, particularly when paired inspiratory and expiratory scans are performed. Expiratory views demonstrate mosaic , characterized by heterogeneous lung densities with low-attenuation areas representing regions of trapped air that fail to increase in attenuation normally during . This pattern arises from small airway obstruction, allowing visual differentiation of affected lobules. Dynamic expiratory CT enhances quantification of air trapping extent by capturing real-time changes in and volume during forced , enabling scoring of severity across segments. Ventilation-perfusion scintigraphy complements structural imaging by assessing functional air trapping, where delayed tracer washout on ventilation scans indicates obstructive retention in affected regions. A key quantitative metric on expiratory CT is the air trapping index, calculated as the percentage of lung volume with densities below -856 Hounsfield units (HU), which correlates with the degree of small airway disease. Compared to pulmonary function tests, CT imaging provides superior anatomical localization, distinguishing focal from diffuse trapping and identifying heterogeneous involvement not evident in global physiological measures.

Pulmonary Function Tests

Pulmonary function tests play a crucial role in diagnosing and quantifying the functional consequences of air trapping, particularly through assessments of and lung volumes that reveal obstructive patterns and . , the primary screening tool, demonstrates airflow obstruction with a reduced forced expiratory in one second (FEV1) to forced (FVC) ratio below 0.7, reflecting narrowed airways and incomplete emptying. However, FVC may appear normal or decreased due to air trapping, which can obscure the severity of air trapping detectable only via volumetric measurements. Lung volume measurements provide direct evidence of air trapping, characterized by an elevated residual volume (RV) exceeding 120% of predicted values and an RV/total lung capacity (TLC) ratio greater than 35%, indicating significant retention of gas post-expiration. These hallmarks arise from dynamic airway collapse, leading to uneven ventilation and increased end-expiratory lung volume. Body plethysmography offers the most accurate RV assessment by measuring total thoracic gas volume via Boyle's law, encompassing trapped air in non-communicating spaces, while helium dilution techniques systematically underestimate RV in obstructed lungs as the inert gas does not equilibrate with poorly ventilated regions. The diffusing capacity of the lung for carbon monoxide (DLCO) further differentiates underlying pathology, often reduced below 80% of predicted in air trapping associated with emphysema due to diminished alveolar-capillary surface area for gas exchange, whereas it remains normal in pure small airway diseases without parenchymal destruction. Air trapping is quantified by the residual volume (RV), derived from static lung volumes as RV=TLC−VC,\text{RV} = \text{TLC} - \text{VC}, where total lung capacity (TLC) is the maximum lung volume at full inspiration, and vital capacity (VC) is the maximum expiratory volume from full inspiration, comprising inspiratory capacity (IC) plus expiratory reserve volume (ERV); IC itself includes tidal volume (TV) and inspiratory reserve volume (IRV). This calculation highlights the trapped fraction when RV is disproportionately elevated relative to predicted norms.

Management and Prognosis

Treatment Approaches

Treatment of air trapping primarily involves pharmacological and procedural interventions aimed at reducing airway obstruction and , particularly in conditions like (COPD) and . Bronchodilators form the cornerstone of therapy, with short-acting beta-agonists (SABAs) such as albuterol providing rapid relief for acute episodes by relaxing bronchial and improving expiratory flow, thereby alleviating dynamic air trapping. For chronic management, long-acting muscarinic antagonists (LAMAs) like tiotropium are recommended, as they enhance lung function, reduce dyspnea, and decrease air trapping at rest and during exercise by promoting sustained bronchodilation. Anti-inflammatory agents target underlying contributing to obstruction. In , inhaled corticosteroids (ICS) such as fluticasone are essential for persistent cases, reducing airway hyperresponsiveness and obstruction that lead to air trapping, with low-dose ICS-formoterol preferred as maintenance and reliever therapy to minimize risk. For COPD, ICS are added to dual therapy in severe cases with frequent or elevated blood (≥300 cells/µL), while phosphodiesterase-4 inhibitors like are indicated for patients with chronic bronchitis to further reduce and frequency. Recent advances include ensifentrine, an inhaled dual phosphodiesterase 3/4 inhibitor approved by the FDA in June 2024, recommended as an add-on to dual therapy for patients with persistent dyspnea. Biologics such as , approved in September 2024, and , approved in May 2025, are indicated for add-on maintenance in adults with COPD (blood ≥300 cells/µL) and inadequately controlled disease despite standard therapy, reducing moderate-to-severe risk by approximately 20-30% in clinical trials. Advanced procedural therapies are reserved for severe emphysema-associated air trapping unresponsive to . Bronchoscopic lung volume reduction, including endobronchial valves (e.g., Zephyr valves), redirects from hyperinflated lobes to healthier regions, improving forced expiratory in 1 second (FEV1) by up to 100 mL and exercise capacity in heterogeneous without collateral ventilation. Ventilation strategies address dynamic in acute or chronic settings. Non-invasive positive pressure ventilation, such as bilevel positive airway pressure (BiPAP), counters air trapping by optimizing expiratory time and reducing , with success rates of 80-85% in hypercapnic associated with COPD exacerbations. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines advocate a stepwise escalation of therapy based on air trapping severity, starting with single long-acting bronchodilators for mild cases and progressing to dual or triple therapy, plus advanced interventions for severe . Similar principles apply in per Global Initiative for Asthma (GINA) recommendations, emphasizing early ICS integration to prevent progression of obstruction.

Prognosis and Complications

The prognosis of air trapping depends on its underlying etiology and reversibility. In reversible conditions such as , air trapping often responds well to treatment with inhaled corticosteroids, potentially allowing full resolution of airflow obstruction and restoration of normal function in many patients. In contrast, irreversible causes like are associated with a poorer outlook, characterized by progressive function decline, including an annual forced expiratory volume in 1 second (FEV1) loss of approximately 50-70 mL in affected individuals. This decline accelerates with continued and emphysema severity, contributing to worsening over time. Complications of persistent air trapping arise primarily from chronic and structural lung damage. Cor pulmonale, or right ventricular enlargement and dysfunction, develops due to increased pulmonary vascular resistance and from sustained in conditions like COPD. Additionally, the presence of emphysematous bullae heightens the risk of through rupture, which can lead to acute and requires urgent intervention. Air trapping severity, as measured by residual volume/total lung capacity (RV/TLC) ratio, correlates directly with exacerbation frequency in COPD; for instance, a 10% increase in RV/TLC elevates the risk of moderate-to-severe exacerbations by 35%. Globally, air trapping as a feature of COPD contributes to substantial mortality, with COPD accounting for approximately 3.5 million deaths in 2021, predominantly in low- and middle-income countries. Monitoring involves serial pulmonary function tests to assess progression of air trapping through metrics like RV/TLC and FEV1, enabling early detection of deterioration. impacts are evaluated using tools such as the St. George's Respiratory Questionnaire (SGRQ), which quantifies respiratory symptoms and functional limitations associated with . offers partial reversal potential in early COPD, slowing air trapping progression and improving lung function by reducing and , though full recovery is unlikely in advanced stages. Treatments like bronchodilators may further mitigate trapping during monitoring.

References

  1. https://www.atsjournals.org/doi/10.1513/AnnalsATS.201311-390OC
  2. https://www.mayoclinic.org/diseases-conditions/emphysema/expert-answers/hyperinflated-lungs/faq-20058169
  3. https://radiopaedia.org/articles/air-trapping?lang=us
  4. https://www.ncbi.nlm.nih.gov/medgen/534054
  5. https://www.tandfonline.com/doi/full/10.3109/15412555.2015.1043521
  6. https://www.atsjournals.org/doi/full/10.1513/pats.200508-094DO
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC8965692/
  8. https://medlineplus.gov/ency/anatomyvideos/000018.htm
  9. https://training.seer.cancer.gov/anatomy/respiratory/mechanics.html
  10. https://pmc.ncbi.nlm.nih.gov/articles/PMC4629724/
  11. https://pmc.ncbi.nlm.nih.gov/articles/PMC12510933/
  12. https://www.ncbi.nlm.nih.gov/books/NBK539907/
  13. https://pressbooks.lib.vt.edu/pulmonaryphysiology/chapter/ventilation-and-perfusion/
  14. https://www.ncbi.nlm.nih.gov/books/NBK493170/
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC2699957/
  16. https://pmc.ncbi.nlm.nih.gov/articles/PMC9135024/
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC3479443/
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC6620562/
  19. https://www.ncbi.nlm.nih.gov/books/NBK526070/
  20. https://www.ncbi.nlm.nih.gov/books/NBK7223/
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC9886194/
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC5846311/
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC9855693/
  24. https://www.ncbi.nlm.nih.gov/books/NBK482217/
  25. https://www.ncbi.nlm.nih.gov/books/NBK559281/
  26. https://www.ncbi.nlm.nih.gov/books/NBK430901/
  27. https://www.ncbi.nlm.nih.gov/books/NBK441865/
  28. https://www.sciencedirect.com/science/article/pii/S1569199313001033
  29. https://www.ncbi.nlm.nih.gov/books/NBK554442/
  30. https://radiopaedia.org/articles/airway-foreign-bodies-in-children?lang=us
  31. https://www.ncbi.nlm.nih.gov/books/NBK441904/
  32. https://www.tandfonline.com/doi/full/10.3109/15412555.2011.565090
  33. https://www.ncbi.nlm.nih.gov/books/NBK519506/
  34. https://erj.ersjournals.com/content/26/5/909
  35. https://www.medicalnewstoday.com/articles/air-trapping-in-lungs
  36. https://www.healthline.com/health/emphysema-air-trapping
  37. https://www.everydayhealth.com/copd/chronic-bronchitis-vs-emphysema-whats-the-difference/
  38. https://emedicine.medscape.com/article/2129484-overview
  39. https://pubmed.ncbi.nlm.nih.gov/32972985/
  40. https://www.mdcalc.com/calc/4006/mmrc-modified-medical-research-council-dyspnea-scale
  41. https://pmc.ncbi.nlm.nih.gov/articles/PMC6330798/
  42. https://emedicine.medscape.com/article/298283-clinical
  43. https://meded.ucsd.edu/clinicalmed/lung.html
  44. https://med.stanford.edu/stanfordmedicine25/the25/pulmonary.html
  45. https://www.merckmanuals.com/professional/pulmonary-disorders/approach-to-the-pulmonary-patient/evaluation-of-the-patient-with-pulmonary-issues
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC11227310/
  47. https://radiopaedia.org/articles/lung-hyperinflation-1?lang=us
  48. https://ajronline.org/doi/10.2214/AJR.11.7067
  49. https://ajronline.org/doi/10.2214/ajr.182.1.1820081
  50. https://www.ncbi.nlm.nih.gov/books/NBK560828/
  51. https://www.atsjournals.org/doi/10.1513/AnnalsATS.201705-377FR
  52. https://www.sciencedirect.com/science/article/abs/pii/S0720048X15000790
  53. https://www.atsjournals.org/doi/10.1164/rccm.201908-1590ST
  54. https://internal.medicine.ufl.edu/files/2012/06/5.12.02-How-to-Interpret-Pulmonary-Function-Tests.pdf
  55. https://www.atsjournals.org/doi/10.1513/AnnalsATS.202405-527OC
  56. https://www.thoracic.org/statements/resources/pft/pft3.pdf
  57. https://www.ncbi.nlm.nih.gov/books/NBK556149/
  58. https://goldcopd.org/wp-content/uploads/2024/11/GOLD-2025-Report-v1.0-15Nov2024_WMV.pdf
  59. https://ginasthma.org/wp-content/uploads/2025/05/GINA-2025_tracked-for-archive-WMSA.pdf
  60. https://www.fda.gov/news-events/press-announcements/fda-approves-first-inhaled-medication-combined-bronchodilator-copd-ensifentrine
  61. https://www.fda.gov/news-events/press-announcements/fda-approves-new-add-on-medication-ease-breathing-adults-copd
  62. https://www.gsk.com/en-gb/media/press-releases/nucala-mepolizumab-approved-by-us-fda/
  63. https://www.sciencedirect.com/science/article/pii/S0954611112000807
  64. https://pmc.ncbi.nlm.nih.gov/articles/PMC3282601/
  65. https://www.atsjournals.org/doi/10.1164/rccm.201111-1938ED
  66. https://pmc.ncbi.nlm.nih.gov/articles/PMC2695205/
  67. https://pmc.ncbi.nlm.nih.gov/articles/PMC7125821/
  68. https://pubmed.ncbi.nlm.nih.gov/35372402/
  69. https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-%28copd%29
  70. https://www.news-medical.net/health/Pulmonary-Function-Tests-in-COPD-Progression-Monitoring.aspx
  71. https://www.thoracic.org/members/assemblies/assemblies/srn/questionaires/sgrq.php
  72. https://pmc.ncbi.nlm.nih.gov/articles/PMC8049901/
  73. https://www.uptodate.com/contents/dynamic-hyperinflation-in-patients-with-copd
Add your contribution
Related Hubs
User Avatar
No comments yet.